

# Clinical Decision Support Systems in Ophthalmology: A Systematic Search and a Narrative Review

Mehrdad MOTAMED SHARIATI\* and Arash DARVISH

Eye Research Center, Mashhad University of Medical Sciences, Gharani Boulevard, 9177833719, Mashhad, Iran.  
E-mails: \*Mehrdad\_shariati2005@yahoo.com; Arachedarviche@gmail.com

\* Author to whom correspondence should be addressed;

Received: 2 September 2024/Accepted: 26 September 2024/ Published online: 29 September 2024

## Abstract

*Purpose:* Clinical decision support systems (CDSS) are advanced tools that enhance clinical decision-making by integrating patient data with evidence-based evidence. In ophthalmology, these systems can potentially improve diagnostic accuracy, optimize treatment plans, and streamline patient management. This narrative review aimed to explore the current landscape of CDSS in ophthalmology, evaluating its applications, benefits, and limitations. *Methods:* A systematic literature review was conducted, focusing on publications from the past decade that discuss the development, implementation, and efficacy of CDSS in ophthalmology. PubMed, Scopus and Web of Science databases were searched using relevant keywords. Articles were selected based on their relevance to clinical outcomes, technological innovation, and integration into ophthalmic practice. *Results:* The review identified various CDSS applications in ophthalmology, including tools for diagnosing retinal diseases, glaucoma management, and diabetic retinopathy screening. These systems leverage artificial intelligence (AI) and machine learning (ML) algorithms to provide real-time support to clinicians. Despite their potential, challenges such as data integration, user adoption, and regulatory approval remain significant barriers to widespread implementation. *Conclusion:* Clinical decision support systems in ophthalmology offer promising avenues for enhancing patient care and clinical efficiency. However, further research and development are necessary to address current limitations and ensure these systems are effectively integrated into routine ophthalmic practice.

**Keywords:** Clinical Decision Support Systems (CDSS); Ophthalmology; Artificial Intelligence (AI) in Healthcare; Diagnostic Tools; Machine Learning

## Introduction

Clinical Decision Support Systems (CDSS) are advanced technologies that integrate patient-specific information with medical knowledge to assist clinicians in making data-driven decisions. The fundamental definition and components of CDSS are well articulated across various studies [1]. Clinical Decision Support Systems integrate complex medical knowledge and algorithms into clinical settings to enhance diagnostic efforts and improve patient safety. These systems typically include computer-based programs that provide differential diagnoses based on clinical inputs. They also encompass tools like antibiotic management programs and anticoagulation dosing calculators [2].

Studies further emphasize the crucial role of CDSS in evidence-based medicine. They underscore that CDSS aid in capturing research and practice-based evidence into machine-interpretable repositories, thus bolstering clinical decisions with current medical knowledge [3]. The studies also emphasize the importance of establishing sustainable technical and methodological foundations and adopting best practices for workflow-sensitive implementations [4, 5].

Advancements in computing power, the availability of large datasets, and the development of sophisticated algorithms have influenced the evolution of CDSS in ophthalmology [6]. Early systems were rule-based, providing simple if-then recommendations based on pre-programmed clinical guidelines [7], but have evolved into complex, data-driven models capable of learning from new data and offering personalized recommendations [8]. Balyen et al. discuss the transformative role of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in automating ophthalmic diagnostics, especially for diseases like diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma [9]. Artificial intelligence-based algorithms significantly enhance diagnosing, managing, and predicting ophthalmic conditions such as DR, glaucoma, and AMD [9]. The efficacy of AI have been highlighted, particularly deep learning, in improving diagnostic accuracy and treatment planning for DR, with models achieving high sensitivity and specificity in diverse settings [10, 11]. In glaucoma, AI models enhance detection and monitoring accuracy, leveraging advanced techniques like active and transfer learning [12, 13]. Artificial intelligence demonstrates potential in severity stratification and progression prediction for AMD, providing performance comparable to human graders [14, 15]. Collectively, these advancements underscore the transformative potential of AI-powered clinical decision support systems in enhancing ophthalmic care.

Despite major advancements in CDSS across fields such as radiology and oncology, integrating these systems into ophthalmology continues to evolve. Studies indicate that regulatory approvals, clinician trust, and system interoperability hinder AI adoption in ophthalmic practice [11, 16, 17].

This narrative review explored the current landscape of CDSS in ophthalmology, highlighting its applications, benefits, and challenges. We examined various AI-powered CDSS across different ophthalmic subspecialties, including DR, glaucoma, and AMD. The review discusses how these systems leverage advanced imaging techniques, such as fundus photography, optical coherence tomography [OCT], and adaptive optics, to enhance diagnostic accuracy and treatment planning. We also explore the integration of machine learning and deep learning algorithms in CDSS, which have shown promising results in automated disease detection and classification. The potential of CDSS to improve clinical workflow, reduce diagnostic errors, and enhance patient care is evaluated. Additionally, we address the challenges in implementing CDSS in ophthalmology, including issues of interpretability, user acceptance, and integration into existing clinical workflows.

## Materials and Methods

### Search Strategy

A well-planned search strategy is essential to obtain data. Various sources were analyzed, including conference papers, journal papers, case studies, etc. Furthermore, websites containing pertinent keywords, such as "Ophthalmology" and "clinical decision support systems for ophthalmology," were searched. Table 1 provides the search terms and search strategy.

**Table 1.** Search strategy summary.

Items	Specifications
Date of Search	Feb 1 <sup>st</sup> , 2024 (first search), Aug 1 <sup>st</sup> 2024 (second search)
Databases and other sources searched	IEEE, Google Scholar, PubMed, Scopus, Web of Science
Search terms used	“Ophthalmology”, “Age-related macular degeneration”, “Diabetic retinopathy”, “Glaucoma”, “Clinical decision support systems”, “AI”, “Machine learning”, “Optical imaging”, “OCT”
Timeframe	Jan 1 <sup>st</sup> 2000–Aug 1 <sup>st</sup> 2024
Inclusion Criteria	Only papers written in English and published between the years 2000 and 2024 were considered for inclusion
Selection process	Both authors were involved in the literature review, manuscript drafting, and revision.

## Types of Clinical Decision Support Systems in Ophthalmology

### *Rule-Based Systems*

Among the earliest decision support tools were rule-based CDSS. The functioning of these systems relies on “if-then” logic, where pre-established rules steer clinical choices. Rule-based systems are frequently employed in ophthalmology to manage prevalent conditions such as DR. For instance, by analyzing a patient’s retinal examination data, the system can suggest appropriate follow-up intervals or specific tests depending on the severity of retinal changes. While these systems are straightforward to implement, their limitations include a lack of flexibility and an inability to adapt to complex cases where clinical nuances are critical [18-20].

### *Machine Learning-Based Systems*

Machine Learning (ML) has revolutionized CDSS by allowing systems to learn from extensive datasets and improve their accuracy. Machine learning-based clinical decision support systems (CDSS) in ophthalmology can predict disease progression, customize treatment strategies, and even detect conditions with a precision level comparable to that of human specialists [21, 22]. In a 2024 study, researchers developed and compared various machine learning methods to predict the final vision prognosis of patients with OGI. The artificial neural network (ANN) model exhibited the highest performance, with the sensitivity, F1 score, positive predictive value (PPV), and accuracy of the ANN model being 0.81, 0.85, 0.89, and 0.93, respectively [23]. Machine Learning -based systems excel in handling vast and complex datasets, rendering them essential in addressing a wide array of ophthalmic conditions [24, 25]. Nonetheless, the lack of transparency in these systems, which obscures the decision-making process, remains a challenge.

### *Image Analysis and Pattern Recognition Systems*

In ophthalmology, imaging techniques such as fundus photography, optical coherence tomography [OCT], and visual field testing play a significant role. The CDSS for image analysis utilizes sophisticated algorithms to examine the images, detecting patterns and irregularities that might show a disease [26, 27]. For example, systems that analyze OCT images can detect macular degeneration or glaucoma by measuring retinal layer thickness or identifying characteristic patterns of damage [28, 29]. These tools assist ophthalmologists by providing a second opinion, reducing diagnostic errors, and enabling earlier detection of diseases.

### *Clinical Pathway-Based Systems*

By incorporating clinical guidelines and pathways, these CDSSs help guide clinicians in delivering standardized care processes. Ophthalmology employs such systems to ensure adherence to best practices in procedures such as cataract surgery or glaucoma management. The use of real-time prompts and reminders in these systems helps minimize variations in care and increase compliance with evidence-based practices [30, 31]. They have a vital role in ensuring that all necessary steps are followed in patient management, reducing the risk of oversight. Nevertheless, these systems may exhibit rigidity and might not always cater to individual patient scenarios.

### *Electronic Health Record -Integrated Systems*

Clinical Decision Support Systems are increasingly being linked with Electronic Health Records (HER), enabling seamless access to patient information and facilitating real-time decision support. Electronic Health Record -integrated CDSS in ophthalmology can improve efficiency by automatically detecting abnormal test results, suggesting appropriate next steps, and identifying patients at risk for specific conditions [32, 33]. The integration with EHR ensures that the decision support is contextually relevant and aligned with the patient’s medical history.

## **Applications of Electronic Health Record in Ophthalmology**

### *Enhancing Diagnostic Accuracy*

Improving diagnostic accuracy is one of the key benefits of using CDSS in ophthalmology. Ocular conditions such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma often present with subtle or

intricate symptoms that can pose challenges in early detection [34, 35]. Recent advances in deep learning have shown promise in surpassing traditional methods for detecting age-related macular degeneration (AMD) and diabetic retinopathy (DR) [36]. Current studies focus on integrating explainable AI (XAI) to boost clinician trust and system transparency, addressing a critical barrier to CDSS adoption in ophthalmology [37]. Electronic Health Record, especially those integrated with advanced imaging technologies, plays a crucial role in early detection and accurate diagnosis (Table 2).

#### *a. Diabetic Retinopathy Screening*

Diabetic retinopathy is a leading cause of blindness worldwide, and early detection is vital for preventing disease progression [38]. Clinical Decision Support Systems can help automate the analysis of retinal images, detecting microaneurysms, hemorrhages, and other signs of retinopathy [39]. By employing pattern recognition algorithms, these systems can evaluate the severity of retinopathy and help clinicians identify high-risk patients who need immediate intervention. Many studies have mentioned the application of supervised ML methods including support vector machine (SVM), naïve Bayes (NB), decision tree (DT), and K-nearest neighbors (KNN), and deep learning algorithms including convolutional neural networks (CNN) in screening and early diagnosis of diabetic retinopathy [10, 40]. Using 243 retinal images from Kaggle's EyePACS dataset, Lam et al. [41] have created an algorithm for DR identification and have produced 1324 image patches to recognize hemorrhages (Hes), microaneurysms (Mas), exudates (Exs), and neo-vessels (NV) from normal structures. 274 image patches are used for testing and 1050 image patches are used for training the CNN model. The model has scanned the picture patches using a  $128 \times 128 \times 3$  patch-trained GoogleLeNet-v1 CNN sliding window to detect MAs and HEs and produce a probability score for each of the five classes of DR. AlexNet, VGG16, GoogLeNet, ResNet, and Inception-v3 have all been compared with the model's performance on 274 test patches. The model has obtained five-class binary classification accuracy of 74% and 79%, 86% and 90%, 95% and 98%, 92% and 95%, and 96% and 98%, respectively [41]. An ensemble CNN method based on LeNet architecture has been presented by Orlando et al. for the identification of HEs and MAs in DR detection. Pre-processing using r-polynomial transformation, noise reduction with a Gaussian filter, noise avoidance with morphological operations, and image patching to restore feasible red lesions have all been incorporated into the technique. The CNN is trained using weight decay, cross-entropy loss function, and stochastic gradient descent (SGD). The Standard Diabetic Retinopathy Database (DIARETDB1), MESSIDOR, and e-Ophtha are some of the datasets that the model has been trained on and utilized for per-lesion identification and image-level validation. For a False Positive per Image (FPI) value of 1, in the interval  $[1/8, 1/4, 1/2, 1, 2, 4, 8]$ , the model has obtained per lesion sensitivity of 0.2885, 0.202, and 0.2 for combined, CNN, and hand-crafted features, respectively been observed for MAs detection in the DIARETDB1 dataset [42].

#### *b. Age-Related Macular Degeneration*

Age-Related Macular Degeneration (AMD) is another condition where early detection is crucial. In ophthalmology, CDSS can analyze Optical Coherence Tomography (OCT) scans to identify early signs of AMD, such as drusen deposits or irregularities in the retinal pigment epithelium (RPE). These systems assist ophthalmologists in making accurate diagnoses and initiating treatment early to prevent significant vision loss by examining retinal layers in great detail [43, 44]. Several studies have highlighted the use of supervised ML methods, including SVM, NB, DT, and KNN, in screening and early diagnosis of AMD [45, 46]. However, the majority of them have demonstrated satisfactory outcomes with the use of CNN. In 2019, Burlina et al. [36] utilized CNN as the classifier to identify various stages of AMD from fundus images. The primary focus of the study was to determine whether deep learning could generate fundus images of age-related macular degeneration (AMD) that retinal experts would perceive as realistic. Two retina specialists conducted equivalent diagnoses on actual versus synthetic images. When diagnosing referable versus non-referable AMD, retinal specialist 1 achieved an accuracy of 84.54% (error margin, 4.06%) on real images compared to 84.12% (error margin, 4.16%) on synthetic images, while retinal specialist 2's accuracy was 89.47% (error margin, 3.45%) on real images versus 89.19% (error margin, 3.54%) on synthetic images [36].

#### *c. Glaucoma Detection*

Glaucoma is characterized by the gradual deterioration of the optic nerve, often associated with elevated intraocular pressure. Through the analysis of visual field tests, OCT scans, and optic nerve images, CDSS can effectively detect changes indicative of glaucoma. For instance, existing systems can identify abnormalities in the retinal nerve fiber layer (RNFL) thickness, a key indicator of glaucoma, prompting further clinical evaluation. These tools are instrumental in the early diagnosis of glaucoma, a critical step in preventing irreversible vision loss [47-49].

#### *Optimizing Treatment Planning*

Besides diagnosing patients, CDSS plays a crucial role in optimizing personalized treatment plans for individual patients, which is paramount in ophthalmology. Tailored treatment strategies can profoundly influence patient outcomes.

##### *a. Cataract Surgery Planning*

Precise preoperative planning is essential for successful outcomes in cataract surgery, a commonly performed procedure in ophthalmology. CDSS can assist in calculating the power of intraocular lenses [IOLs] by integrating patient-specific details such as axial length, corneal curvature, and anterior chamber depth. These systems enhance visual outcomes and reduce the likelihood of postoperative refractive errors by providing surgeons with optimized IOL options [50, 51]. In addition to diagnostics, CDSS shows promise in optimizing surgical procedures. For example, AI-based systems are increasingly employed for preoperative planning in cataract surgeries, guiding the selection of intraocular lenses (IOL) based on patient-specific factors such as corneal curvature and axial length. These systems enhance precision and improve postoperative outcomes [50].

##### *b. Management of Retinal Diseases*

Opting for the treatment of retinal diseases such as AMD and diabetic macular edema often involves choosing between different anti-VEGF agents or laser therapies. Analyzing patient-specific factors, including disease severity, previous treatment responses, and genetic markers, allows CDSS to offer guidance for these decisions. For example, a CDSS could suggest the most appropriate anti-VEGF medication based on the patient's genetic predisposition to respond to a particular drug. This personalized strategy improves treatment efficacy [52].

##### *c. Glaucoma Management*

Balancing the reduction of intraocular pressure and minimizing side effects is crucial in glaucoma treatment. CDSS can facilitate this by providing personalized treatment plans, which may involve the optimal combination of medications or surgical interventions. Considering factors like disease progression rate, patient compliance, and comorbidities, these systems assist clinicians in choosing the most effective treatment options [48, 53].

#### *Improving Patient Monitoring and Follow-Up*

Ophthalmology necessitates ongoing monitoring of chronic conditions to prevent disease progression and effectively manage complications. Clinical Decision Support System can play a crucial role in patient monitoring and follow-up, ensuring that patients receive timely care.

##### *a. Automated Monitoring Systems*

In cases such as diabetic retinopathy and glaucoma, where consistent follow-up is crucial, CDSS can be integrated with telemedicine platforms to automate patient monitoring. For instance, home monitoring devices can transmit data directly to a Clinical Decision Support System [CDSS]. Subsequently, the CDSS evaluates the data and alerts healthcare providers of any signs of disease progression. This integration allows clinics to optimize their resources, leading to enhanced patient care accessibility and decreased burden [54, 55].

##### *b. Predictive Analytics for Disease Progression*

Predictive analytics can be used by CDSS to evaluate the probability of disease progression in individuals with chronic eye conditions. These systems can analyze longitudinal data from EHRs to forecast which patients are susceptible to deterioration and may require increased monitoring or timely intervention. When dealing with glaucoma, a CDSS could scrutinize trends in intraocular pressure and visual field degradation to anticipate the likelihood of rapid advancement. Such insights would empower clinicians to adjust treatment approaches accordingly [56, 57].

*Supporting Clinical Research and Evidence-Based Practice*

Clinical Decision Support System also plays a crucial role in advancing clinical research and promoting evidence-based practice in ophthalmology. By utilizing extensive datasets and integrating clinical guidelines, these systems can generate innovative insights and promote the implementation of optimal approaches.

*a. Data-Driven Research*

By analyzing extensive clinical data, CDSS can detect patterns, relationships, and outcomes associated with different ophthalmic treatments. This skill is advantageous in producing practical evidence that can inform clinical practice guidelines [58, 59]. For example, by analyzing data from multiple cataract surgeries, a computerized decision support system (CDSS) could identify the factors that affect the effectiveness of different intraocular lens [IOL] types in specific groups of patients. This would improve surgical techniques and the overall outcomes for patients.

*b. Guideline Adherence*

It is crucial to adhere to clinical guidelines to uphold high standards of care in ophthalmology. CDSS can aid clinicians by offering immediate reminders and recommendations that are in line with the most recent guidelines. For instance, when dealing with diabetic retinopathy, a computerized decision support system [CDSS] can remind the healthcare provider to conduct particular tests or adhere to specific protocols, guaranteeing that the patient receives treatment according to the most current evidence available [59].

We summarize the previous studies’ purpose and main findings considering the designing and applications of various clinical decision-supporting systems in ophthalmology in Table 2.

**Table 2.** Literature review summary considering various types of AI-based CDSS in ophthalmology.

<b>Authors [year]</b>	<b>Purpose</b>	<b>Main Findings</b>
Kahai et al. (2006) [60]	Designing a CDSS for automatic screening of diabetic retinopathy.	In terms of classifying microaneurysms, the system's sensitivity is 100% and its specificity is 67%. About 10 nanoseconds is the computing time, which mostly depends on the detecting technique.
Chia-Ling et al. (2008) [61]	To present the retinal image vessel extraction and registration system, an integrated suite of cutting-edge digital tools for retinal image analysis that is available to the community of retinal physicians, researchers, and study directors.	Significant progress in retina-related clinical diagnosis, analysis of longitudinal changes, research on the retinal vasculature, visualization of the entire fundus at full resolution from multiple low-angle views, and objective, quantitative computer-assisted scoring of clinical trial imagery can all be made possible by this integrated Internet-based system.
Jegelevicius et al. (2009) [62]	A web-based application for signal and image analysis techniques and algorithms, as well as a database of clinical data, are needed to construct a prototype of a network-based clinical decision support system.	Clinical decision support may take a comprehensive approach with the use of network-based databases and integrated analysis of the parameters acquired by applied techniques.
Skevofilakas et al. (2010) [63]	To create a Decision Support System (DSS) that can predict a	The DSS is a hybrid architecture that combines an enhanced Hybrid Wavelet Neural Network (iHWNN) with a Feedforward Neural

Authors [year]	Purpose	Main Findings
	patient's risk of developing retinopathy in individuals with Type 1 Diabetes Mellitus (T1DM).	Network (FNN), a Classification and Regression Tree (CART), and a Rule Induction C5.0 classifier. The DSS has shown an excellent performance resulting in an accuracy of 98%.
Kumar et al. (2012) [64]	To design a CDSS to predict diabetic retinopathy from fundus images.	The retrieved data includes the vein diameter, main and branch vessel thickness, and optic disc parameters. For classification, various types of neural networks have been employed. The SVM classifier is discovered to have a lower rate of false rejection and acceptance than other classifiers. After verification, the suggested system's accuracy was 97.47%.
Fraz et al. (2013) [65]	This study presents a linear discriminant analysis-based approach for segmenting retinal blood vessels based on pixel classification.	The three publicly accessible DRIVE, STARE, and MESSIDOR datasets are used to assess the methodology. The technique is a good tool for automated retinal image analysis since it is computationally quick and performs similarly to other approaches that have been published in the literature.
Prasanna et al. (2013) [66]	To propose a low-cost and portable smartphone-based decision support system for initial diabetic retinopathy screening using sophisticated image analysis and machine learning techniques.	The average sensitivity of the CDSS system to detect diabetic retinopathy based on fundus images was 86%.
Bourouis et al. (2014) [67]	To design a mobile-based intelligent CDSS for retinal disease diagnosis.	This mobile diagnosis device analyzes the retinal images obtained by the microscopic lens using an artificial neural network algorithm to diagnose retinal disease. According to the evaluation results, the system has an accuracy rate >87% for detecting retinal diseases.
Romero Aroca et al. (2019) [18]	To develop a CDSS for diabetic retinopathy screening.	A fuzzy random forest, or collection of fuzzy decision trees, was the foundation of the CDSS. Predicting features include current age, gender, DM duration and treatment, arterial hypertension, body mass index, HbA1c, estimated glomerular filtration rate, and microalbuminuria. The accuracy of the CDSS was 80.76%, sensitivity was 80.67%, and specificity was 85.96%
Sajitha et al. (2021) [68]	Using machine-learning models to diagnose glaucoma.	The Naïve Bayes classifier, linear and kernel Support Vector classifiers, decision tree classifier, Adaboost, random forest, and eXtreme Gradient Boosting (XGBoost) classifier were the seven classifiers that were compared in the suggested system. The discrimination of eye gaze features of glaucoma and normal is efficiently done by XGBoost with an accuracy of 1.0.
Hwang et al. (2019) [69]	Using the convolutional neural networks to diagnose AMD based on OCT images.	The detection accuracy of the AI platform was consistently above 90%, much better ( $p < 0.001$ ) than that of medical students (69.4% and 68.9%) and comparable ( $p = 0.99$ ) to that of retinal experts (92.73% and 91.90%).
Emde et al. (2019) [70]	To develop a machine learning method to predict the mesopic and dark-adapted [DA] retinal sensitivity of neovascular age-related macular degeneration [nAMD] eyes.	In upcoming clinical studies, this artificial intelligence-based analytical technique—referred to as "inferred sensitivity"—may be utilized as a quasi-functional surrogate endpoint to assess the distinct impacts of retinal structural abnormalities on cone and rod function in nAMD.
Heo et al. (2020) [71]	To develop a deep learning-based CDSS for AMD diagnosis using fundus images.	In comparison to manual review by first-year residents, the prediction and validation findings produced using the AI AMD diagnosis model demonstrated relevant performance and appropriateness as well as superior diagnostic accuracy.

<b>Authors [year]</b>	<b>Purpose</b>	<b>Main Findings</b>
Abramov et al. (2018) [72]	Using deep learning algorithms for DR screening.	Demonstrated high diagnostic accuracy [sensitivity 87.2%, specificity 90.7%] comparable to ophthalmologists.
Gulshan et al. (2019) [73]	Using CNN for DR screening.	Achieved sensitivity of 97.5% and specificity of 93.4% in detecting referable diabetic retinopathy.
Burgansky-Eliash et al. (2005) [74]	To investigate whether machine learning models could improve the performance of OCT glaucoma detection.	Using eight parameters, the support vector machine produced the greatest area under the ROC curve [AROC] for the glaucoma diagnosis (0.981).

### *Challenges and Future Directions*

While the applications of CDSS in ophthalmology are vast and promising, some challenges need to be addressed to maximize their potential [35].

#### *a. Integration with Clinical Workflow*

One of the major obstacles is the smooth integration of CDSS into the clinical workflow. If a system is difficult for users to navigate or interrupts the seamless provision of patient care, it may not be adopted on a large scale, regardless of its potential advantages. Therefore, future developments in CDSS should focus on creating intuitive interfaces that complement, rather than complicate, clinical practice [17, 75].

#### *b. Data Privacy and Security*

The use of CDSS involves handling sensitive patient data, which raises concerns about privacy and security. Ensuring that these systems comply with data protection regulations and are secure from cyber threats is essential for maintaining patient trust and protecting healthcare data [76, 77].

#### *c. Transparency*

Many advanced CDSS, particularly those based on machine learning, operate as "black boxes," where the decision-making process is not transparent. This lack of explainability can hinder clinician trust and acceptance of these systems. Future research should focus on developing explainable AI models that provide insights into how decisions are made, thereby increasing clinician confidence in CDSS recommendations [37]. While CDSS holds substantial potential, the 'black box' nature of many AI models poses challenges regarding transparency and clinician trust [75]. To address these concerns, implementing explainable AI (XAI) and ensuring that CDSS comply with strict regulatory standards for patient data privacy is essential for their successful integration into ophthalmic care [75].

Future research should aim to create multi-modal CDSS systems that integrate data from various diagnostic tools like OCT, genetic tests, and patient history [73]. Additionally, it is imperative to conduct longitudinal studies to validate the clinical utility of AI-based CDSS and ensure they are adaptable to diverse patient populations [22].

## **Discussion**

By incorporating Clinical Decision Support Systems (CDSS) in ophthalmology, there is a profound shift towards improving diagnostic accuracy, optimizing treatment protocols, and ultimately enhancing patient outcomes. This narrative review has explored the multifaceted roles of CDSS, underscoring their potential benefits and current limitations.

Using CDSS in ophthalmology has improved data management and decision-making. By using extensive clinical data, these systems enable more precise diagnoses, offer evidence-based recommendations, and improve workflow efficiency. CDSS can be useful in the timely detection and effective management of conditions such as AMD and DR, which are often difficult to diagnose during their initial phases. By using advanced algorithms and machine



learning techniques, CDSS can accurately analyze retinal images and other diagnostic data. This might help identify abnormalities that human clinicians may miss.

Implementing CDSS in ophthalmology has shown promising results in improving the quality of care. These systems standardize diagnostic criteria and treatment protocols, resulting in less variation in clinical practices and ensuring more consistent patient care in various settings. Consistency is of utmost importance in ophthalmology, as minor differences in the way diagnostic interpretations are made can have a profound impact on the success of treatments.

Clinical Decision Support Systems improves the ability to provide personalized medical care in ophthalmology. By incorporating patient-specific data, such as genetics, demographics, and medical history, these systems customize treatment plans to meet the unique needs of each individual. Customized recommendations are vital for effectively managing chronic conditions like glaucoma. This is important in ensuring proper control of intraocular pressure and the preservation of vision. Customizing care plans using extensive data sets not only enhances patient outcomes but also maximizes resource utilization.

Despite these advancements, there are still several obstacles that hinder the widespread adoption and implementation of CDSS in ophthalmology. Integrating these systems into current electronic health record [EHR] systems and clinical workflows poses a major challenge. The implementation process can be complicated by problems with interoperability and the need for seamless data exchange. The matter of gaining trust and acceptance from clinicians is also a concern. The success of CDSS relies heavily on users having confidence in the system's recommendations, which can only be achieved through ongoing validation and education.

Clinical Decision Support Systems poses additional challenges regarding ethical and legal concerns. Using automated systems raises concerns regarding who is accountable, especially in diagnostic errors or negative results. Clear guidelines must be established for the use of CDSS, which should clearly outline the responsibilities of both clinicians and the systems. To address these concerns, it is important to make sure that CDSS functions transparently and that clinicians can easily understand and interpret its recommendations.

The quality and representativeness of the data used to train CDSS in ophthalmology plays a crucial role in determining their effectiveness. Diverse and comprehensive datasets are necessary to ensure the effective performance of CDSS in various patient populations and clinical situations. Creating comprehensive and inclusive datasets will play a crucial role in enhancing the precision and applicability of these systems.

Clinical Decision Support Systems in ophthalmology has a bright future ahead, especially with the progress made in artificial intelligence (AI) and machine learning. As these technologies continue to advance, we can expect the development of even more advanced systems that offer real-time decision support and predictive analytics. Further research should prioritize the improvement of these technologies, tackling the previously mentioned obstacles, and confirming the clinical significance of CDSS through extensive multicenter studies.

In summary, implementing Clinical Decision Support Systems in ophthalmology is a significant step forward, as they offer improved diagnostic capabilities, personalized treatment options, and greater consistency in patient care. Despite the existing challenges, including integration, acceptance, and data quality, the potential advantages of CDSS are significant. Through addressing these challenges and pushing the boundaries of technology, CDSS has the potential to become an essential element of modern ophthalmology, ultimately leading to enhanced patient outcomes and more effective healthcare delivery. It is imperative to continually refine these systems to maximize their effectiveness, as the continuous evolution and integration of CDSS will be pivotal in shaping the future of ophthalmology.

To sum up, CDSS in ophthalmology shows potential for improving diagnostic accuracy and treatment planning. However, realizing their full potential depends on ongoing collaboration between AI developers and clinicians to ensure these systems are effectively integrated into clinical workflows and provide timely, actionable insights. Future advancements will hinge on addressing current challenges in data integration, transparency, and regulatory approval.

**List of Abbreviations:** CDSS: Clinical Decision Support Systems, ML: Machine learning, AI: Artificial intelligence, DL: Deep learning, DR: Diabetic retinopathy, AMD: Age-related macular degeneration

**Author contributions:** Both authors were involved in the study design, searching process, literature review, manuscript drafting, and revision.

**Funding:** This research received no funding.

**Ethics Statement:** The authors are accountable for all aspects of the work and ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

## References

1. Beeler PE, Bates DW, Hug BL. Clinical decision support systems. *Swiss medical weekly*. 2014;144:w14073.
2. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. *NPJ digital medicine*. 2020;3(1):17.
3. Musen MA, Middleton B, Greenes RA. Clinical decision-support systems. *Biomedical informatics: computer applications in health care and biomedicine*: Springer; 2021. p. 795-840.
4. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. *Bmj*. 2005;330(7494):765.
5. Hak F, Guimarães T, Santos M. Towards effective clinical decision support systems: A systematic review. *PLoS One*. 2022;17(8):e0272846.
6. Guo Y, Huang C, Sheng Y, Zhang W, Ye X, Lian H, et al. Improve the efficiency and accuracy of ophthalmologists' clinical decision-making based on AI technology. *BMC Medical Informatics and Decision Making*. 2024;24(1):192.
7. Kierner S, Kucharski J, Kierner Z. Taxonomy of hybrid architectures involving rule-based reasoning and machine learning in clinical decision systems: A scoping review. *Journal of Biomedical Informatics*. 2023;144:104428.
8. Ahmad OAB. Diabetic Retinopathy (DR) Prediction by the RuleFit Algorithm Using Routine Lab Results: Oklahoma State University; 2023.
9. Balyen L, Peto T. Promising artificial intelligence-machine learning-deep learning algorithms in ophthalmology. *The Asia-Pacific Journal of Ophthalmology*. 2019;8(3):264-72.
10. Gunasekeran DV, Ting DS, Tan GS, Wong TY. Artificial intelligence for diabetic retinopathy screening, prediction and management. *Current opinion in ophthalmology*. 2020;31(5):357-65.
11. Bellemo V, Lim G, Rim TH, Tan GS, Cheung CY, Sadda S, et al. Artificial intelligence screening for diabetic retinopathy: the real-world emerging application. *Current Diabetes Reports*. 2019;19:1-12.
12. Chayan TI, Islam A, Rahman E, Reza MT, Apon TS, Alam MGR, editors. Explainable AI based glaucoma detection using transfer learning and LIME. 2022 IEEE Asia-Pacific Conference on Computer Science and Data Engineering (CSDE); 2022: IEEE.
13. Kumar Y, Gupta S. Deep transfer learning approaches to predict glaucoma, cataract, choroidal neovascularization, diabetic macular edema, drusen and healthy eyes: an experimental review. *Archives of Computational Methods in Engineering*. 2023;30(1):521-41.
14. Burlina P, Pacheco KD, Joshi N, Freund DE, Bressler NM. Comparing humans and deep learning performance for grading AMD: a study in using universal deep features and transfer learning for automated AMD analysis. *Computers in biology and medicine*. 2017;82:80-6.
15. Chen Y-M, Huang W-T, Ho W-H, Tsai J-T. Classification of age-related macular degeneration using convolutional-neural-network-based transfer learning. *BMC Bioinformatics*. 2021;22:1-16.
16. Bellemo V, Lim ZW, Lim G, Nguyen QD, Xie Y, Yip MY, et al. Artificial intelligence using deep learning to screen for referable and vision-threatening diabetic retinopathy in Africa: a clinical validation study. *The Lancet Digital Health*. 2019;1(1):e35-e44.
17. Gunasekeran DV, Wong TY. Artificial intelligence in ophthalmology in 2020: a technology on the cusp for translation and implementation. *LWW*; 2020. p. 61-6.
18. Romero-Aroca P, Valls A, Moreno A, Sagarra-Alamo R, Basora-Gallisa J, Saleh E, et al. A clinical decision support system for diabetic retinopathy screening: creating a clinical support application. *Telemedicine and e-Health*. 2019;25(1):31-40.

19. Huang S, Liang Y, Li J, Li X. Applications of Clinical Decision Support Systems in Diabetes Care: Scoping Review. *Journal of Medical Internet Research*. 2023;25:e51024.
20. Kim S, Kim E-H, Kim H-S. Physician knowledge base: clinical decision support systems. *Yonsei Medical Journal*. 2022;63(1):8.
21. Vasey B, Ursprung S, Beddoe B, Taylor EH, Marlow N, Bilbro N, et al. Association of clinician diagnostic performance with machine learning–based decision support systems: a systematic review. *JAMA network open*. 2021;4(3):e211276-e.
22. Levy-Fix G, Kuperman GJ, Elhadad N. Machine learning and visualization in clinical decision support: current state and future directions. *arXiv preprint arXiv:190602664*. 2019.
23. Shariati MM, Eslami S, Shoeibi N, Eslampoor A, Sedaghat M, Gharaei H, et al. Development, comparison, and internal validation of prediction models to determine the visual prognosis of patients with open globe injuries using machine learning approaches. *BMC medical informatics and decision making*. 2024;24(1):131.
24. Ting DSW, Pasquale LR, Peng L, Campbell JP, Lee AY, Raman R, et al. Artificial intelligence and deep learning in ophthalmology. *British Journal of Ophthalmology*. 2019;103(2):167-75.
25. Ting DS, Peng L, Varadarajan AV, Keane PA, Burlina PM, Chiang MF, et al. Deep learning in ophthalmology: the technical and clinical considerations. *Progress in Retinal and Eye Research*. 2019;72:100759.
26. Gurevich I, Yashina V, Ablameyko S, Nedzved A, Ospanov A, Tleubaev A, et al. Development and experimental investigation of mathematical methods for automating the diagnostics and analysis of ophthalmological images. *Pattern Recognition and Image Analysis*. 2018;28:612-36.
27. Marrugo AG, Millán MS, Cristóbal G, Gabarda S, Sorel M, Sroubek F, editors. *Image analysis in modern ophthalmology: from acquisition to computer assisted diagnosis and telemedicine. Optics, Photonics, and Digital Technologies for Multimedia Applications II*; 2012: SPIE.
28. Wang L, Zhang K, Liu X, Long E, Jiang J, An Y, et al. Comparative analysis of image classification methods for automatic diagnosis of ophthalmic images. *Scientific Reports*. 2017;7(1):41545.
29. Ilyasova NY, Demin N. Application of artificial intelligence in ophthalmology for the diagnosis and treatment of eye diseases. *Pattern Recognition and Image Analysis*. 2022;32(3):477-82.
30. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. *Retina*. 2010;30(9):1350-67.
31. Tanya SM, Nguyen AX, Buchanan S, Jackman CS. Development of a cloud-based clinical decision support system for ophthalmology triage using decision tree artificial intelligence. *Ophthalmology Science*. 2023;3(1):100231.
32. Goldstein JE, Guo X, Swenor BK, Boland MV, Smith K. Using electronic clinical decision support to examine vision rehabilitation referrals and practice guidelines in ophthalmology. *Translational Vision Science & Technology*. 2022;11(10):8.
33. Felfeli T, Huang RS, Lee T-SJ, Lena ER, Basilious A, Lamoureux D, et al. Assessment of predictive value of artificial intelligence for ophthalmic diseases using electronic health records: A systematic review and meta-analysis. *JFO Open Ophthalmology*. 2024:100124.
34. Galveia JN, Travassos A, da Silva Cruz LA, editors. *An ophthalmology clinical decision support system based on clinical annotations, ontologies and images*. 2018 IEEE 31st International Symposium on Computer-Based Medical Systems (CBMS); 2018: IEEE.
35. Taribagil P, Hogg HJ, Balaskas K, Keane PA. Integrating artificial intelligence into an ophthalmologist's workflow: obstacles and opportunities. *Expert Review of Ophthalmology*. 2023;18(1):45-56.
36. Burlina PM, Joshi N, Pacheco KD, Liu TA, Bressler NM. Assessment of deep generative models for high-resolution synthetic retinal image generation of age-related macular degeneration. *JAMA Ophthalmology*. 2019;137(3):258-64.
37. Chen D, Geevarghese A, Lee S, Plovnick C, Elgin C, Zhou R, et al. Transparency in AI reporting in Ophthalmology-A Scoping Review. *Ophthalmology Science*. 2024;4(4):100471.
38. Vujosevic S, Aldington SJ, Silva P, Hernández C, Scanlon P, Peto T, et al. Screening for diabetic retinopathy: new perspectives and challenges. *The Lancet Diabetes & Endocrinology*. 2020;8(4):337-47.
39. Li S, Zhao R, Zou H. Artificial intelligence for diabetic retinopathy. *Chinese medical journal*. 2022;135(03):253-60.

40. Rajesh AE, Davidson OQ, Lee CS, Lee AY. Artificial Intelligence and Diabetic Retinopathy: AI Framework, prospective studies, head-to-head validation, and cost-effectiveness. *Diabetes care*. 2023;46(10):1728-39.
41. Lam C, Yu C, Huang L, Rubin D. Retinal lesion detection with deep learning using image patches. *Investigative ophthalmology & visual science*. 2018;59(1):590-6.
42. Orlando JI, Prokofyeva E, Del Fresno M, Blaschko MB. An ensemble deep learning based approach for red lesion detection in fundus images. *Computer methods and programs in biomedicine*. 2018;153:115-27.
43. Perepelkina T, Fulton AB, editors. Artificial intelligence (AI) applications for age-related macular degeneration [AMD] and other retinal dystrophies. *Seminars in ophthalmology*; 2021: Taylor & Francis.
44. Bhuiyan A, Wong TY, Ting DSW, Govindaiah A, Souied EH, Smith RT. Artificial intelligence to stratify severity of age-related macular degeneration (AMD) and predict risk of progression to late AMD. *Translational vision science & technology*. 2020;9(2):25.
45. Abd El-Khalek AA, Balaha HM, Sewelam A, Ghazal M, Khalil AT, Abo-Elsoud MEA, et al. A Comprehensive Review of AI Diagnosis Strategies for Age-Related Macular Degeneration (AMD). *Bioengineering*. 2024;11(7): 711.
46. Thakoor KA, Yao J, Bordbar D, Moussa O, Lin W, Sajda P, et al. A multimodal deep learning system to distinguish late stages of AMD and to compare expert vs. AI ocular biomarkers. *Scientific Reports*. 2022;12(1):2585.
47. Yousefi S. Clinical applications of artificial intelligence in glaucoma. *Journal of Ophthalmic & Vision Research*. 2023;18(1):97.
48. Chaurasia AK, Greatbatch CJ, Hewitt AW. Diagnostic accuracy of artificial intelligence in glaucoma screening and clinical practice. *Journal of Glaucoma*. 2022;31(5):285-99.
49. AlRyalat SA, Singh P, Kalpathy-Cramer J, Kahook MY. Artificial intelligence and glaucoma: going back to basics. *Clinical Ophthalmology*. 2023;17:1525-30.
50. Lindegger DJ, Wawrzynski J, Saleh GM. Evolution and applications of artificial intelligence to cataract surgery. *Ophthalmology Science*. 2022;2(3):100164.
51. Gutierrez L, Lim JS, Foo LL, Ng WY, Yip M, Lim GYS, et al. Application of artificial intelligence in cataract management: current and future directions. *Eye and Vision*. 2022;9(1):3.
52. Ho S, Kalloniatis M, Ly A. Clinical decision support in primary care for better diagnosis and management of retinal disease. *Clinical and Experimental Optometry*. 2022;105(6):562-72.
53. Zhang L, Tang L, Xia M, Cao G. The application of artificial intelligence in glaucoma diagnosis and prediction. *Frontiers in cell and developmental biology*. 2023;11:1173094.
54. Pour AM, Seyedarabi H, Jahromi SHA, Javadzadeh A. Automatic detection and monitoring of diabetic retinopathy using efficient convolutional neural networks and contrast limited adaptive histogram equalization. *IEEE Access*. 2020;8:136668-73.
55. Noriega A, Meizner D, Camacho D, Enciso J, Quiroz-Mercado H, Morales-Canton V, et al. Screening diabetic retinopathy using an automated retinal image analysis system in independent and assistive use cases in Mexico: randomized controlled trial. *JMIR formative research*. 2021;5(8):e25290.
56. Zhu Y, Salowe R, Chow C, Li S, Bastani O, O'Brien JM. Advancing glaucoma care: integrating artificial intelligence in diagnosis, management, and progression detection. *Bioengineering*. 2024;11(2):122.
57. Thainimit S, Chaipayom P, Sa-arnwong N, Gansawat D, Petchyim S, Pongrujikorn S. Robotic process automation support in telemedicine: Glaucoma screening usage case. *Informatics in Medicine Unlocked*. 2022;31:101001.
58. Lee CS, Brandt JD, Lee AY. Big data and artificial intelligence in ophthalmology: where are we now? *Ophthalmology Science*. 2021;1(2):100036.
59. Feng X, Xu K, Luo M-J, Chen H, Yang Y, He Q, et al. Latest Developments of Generative Artificial Intelligence and Applications in Ophthalmology. *Asia-Pacific Journal of Ophthalmology*. 2024; 13(4):100090.
60. Kahai P, Namuduri KR, Thompson H. A decision support framework for automated screening of diabetic retinopathy. *International journal of biomedical imaging*. 2006;2006(1):045806.
61. Tsai C-L, Madore B, Leotta MJ, Sofka M, Yang G, Majerovics A, et al. Automated retinal image analysis over the internet. *IEEE Transactions on Information Technology in Biomedicine*. 2008;12(4):480-7.

62. Jegelevicius D, Krisciukaitis A, Lukosevicius A, Marozas V, Paunksnis A, Barzdziukas V, et al., editors. Network based clinical decision support system. 2009 9th International Conference on Information Technology and Applications in Biomedicine; 2009: IEEE.
63. Skevofilakas M, Zarkogianni K, Karamanos BG, Nikita KS, editors. A hybrid Decision Support System for the risk assessment of retinopathy development as a long term complication of Type 1 Diabetes Mellitus. 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology; 2010: IEEE.
64. Kumar SJJ, Madheswaran M. An improved medical decision support system to identify the diabetic retinopathy using fundus images. *Journal of medical systems*. 2012;36:3573-81.
65. Fraz M, Remagnino P, Hoppe A, Barman S, editors. Retinal image analysis aimed at extraction of vascular structure using linear discriminant classifier. 2013 International Conference on Computer Medical Applications (ICCMA); 2013: IEEE.
66. Prasanna P, Jain S, Bhagat N, Madabhushi A, editors. Decision support system for detection of diabetic retinopathy using smartphones. 2013 7th International Conference on Pervasive Computing Technologies for Healthcare and Workshops; 2013: IEEE.
67. Bourouis A, Feham M, Hossain MA, Zhang L. An intelligent mobile based decision support system for retinal disease diagnosis. *Decision Support Systems*. 2014;59:341-50.
68. Krishnan S, Amudha J, Tejwani S. Intelligent-based decision support system for diagnosing glaucoma in primary eyecare centers using eye tracker. *Journal of Intelligent & Fuzzy Systems*. 2021;41(5):5235-42.
69. Hwang D-K, Hsu C-C, Chang K-J, Chao D, Sun C-H, Jheng Y-C, et al. Artificial intelligence-based decision-making for age-related macular degeneration. *Theranostics*. 2019;9(1):232.
70. von der Emde L, Pfau M, Dysli C, Thiele S, Möller PT, Lindner M, et al. Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. *Scientific Reports*. 2019;9(1):11132.
71. Heo T-Y, Kim KM, Min HK, Gu SM, Kim JH, Yun J, et al. Development of a deep-learning-based artificial intelligence tool for differential diagnosis between dry and neovascular age-related macular degeneration. *Diagnostics*. 2020;10(5):261.
72. Abramoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *NPJ digital medicine*. 2018;1(1):39.
73. Gulshan V, Rajan RP, Widner K, Wu D, Wubbels P, Rhodes T, et al. Performance of a deep-learning algorithm vs manual grading for detecting diabetic retinopathy in India. *JAMA ophthalmology*. 2019;137(9):987-93.
74. Burgansky-Eliash Z, Wollstein G, Chu T, Ramsey JD, Glymour C, Noecker RJ, et al. Optical coherence tomography machine learning classifiers for glaucoma detection: a preliminary study. *Investigative ophthalmology & visual science*. 2005;46(11):4147-52.
75. Ramessur R, Raja L, Kilduff CL, Kang S, Li J-PO, Thomas PB, et al. Impact and challenges of integrating artificial intelligence and telemedicine into clinical ophthalmology. *Asia-Pacific Journal of Ophthalmology*. 2021;10(3):317-27.
76. Tom E, Keane PA, Blazes M, Pasquale LR, Chiang MF, Lee AY, et al. Protecting data privacy in the age of AI-enabled ophthalmology. *Translational vision science & technology*. 2020;9(2):36.
77. Grzybowski A. *Artificial intelligence in ophthalmology: promises, hazards and challenges*: Springer; 2021.